Haemonetics Corporation has announced its acquisition of Vivasure Medical Limited, a company based in Galway, Ireland, known for its innovative technology in percutaneous vessel closure. The deal, finalized on January 9, 2026, aims to enhance Haemonetics’ offerings in the medical technology sector, particularly in the area of large-bore closure devices.
Vivasure’s flagship product, the PerQseal Elite system, utilizes a proprietary bioabsorbable patch designed to effectively seal arteriotomies and venotomies. This technology offers a sutureless and fully absorbable solution for patients undergoing structural heart and endovascular procedures. In 2025, Vivasure submitted a Premarket Approval application to the U.S. Food and Drug Administration (FDA) for the PerQseal Elite arterial closure system and successfully received CE Mark approval in Europe for both arterial and venous applications.
The acquisition involves an upfront cash payment of €100 million, which translates to approximately €52 million when accounting for previous investments and loans made by Haemonetics to Vivasure. Additionally, there is a potential for up to €85 million in contingent consideration based on sales growth and the achievement of specific milestones.
Haemonetics is financing the transaction through existing cash reserves. Ken Crowley, Vice President & General Manager of Interventional Technologies at Haemonetics, expressed optimism about the acquisition, stating, “Acquiring Vivasure expands Haemonetics’ complete range of closure devices with new and clinically differentiated technology to bolster our presence in the large-bore closure market.”
The clinical data surrounding the PerQseal Elite system is promising. Results from the multi-center ELITE arterial study demonstrated a 0% rate of major complications at thirty-day follow-up, showcasing its ease of use without the need for pre-closure. Moreover, the median time to achieve hemostasis was immediate, highlighting its effectiveness.
Andrew Glass, Chief Executive Officer of Vivasure Medical Limited, emphasized the significance of this partnership, stating, “Joining Haemonetics provides the global scale and resources to accelerate the availability of PerQseal Elite and bring its clinical benefits to more physicians and patients worldwide.” This collaboration aims to leverage Haemonetics’ commercial scale and operational synergies to enhance the value delivered to healthcare providers.
Founded in Galway, Ireland, Vivasure Medical is dedicated to the development of advanced polymer implants and delivery systems, focusing primarily on minimally invasive vessel closure in cardiology, interventional radiology, and vascular surgery. The company operates a fully integrated research and development facility that meets ISO 13485 standards.
As a leader in medical technology, Haemonetics is committed to improving healthcare quality and efficiency. Its diverse portfolio includes hospital technologies aimed at enhancing patient outcomes, optimizing plasma collection processes for plasma centers, and facilitating blood component collection.
The integration of Vivasure Medical’s innovative technologies into Haemonetics’ offerings is expected to reinforce the company’s position in the fast-evolving market for advanced closure devices. This strategic move aligns with Haemonetics’ mission to address critical medical needs and improve patient care across the globe.
